Lantheus completes $275 million acquisition of Evergreen Theragnostics
Lantheus completed its acquisition of Evergreen Theragnostics on April 1, 2025, paying approximately $275 million in cash at closing. Up to an additional $727.5 million in milestone payments remains potentially payable under the merger agreement, depending on future milestone events. The filing says the deal adds the OCTEVY PET imaging agent and Evergreen's manufacturing business to Lantheus.
Key points
- Cash paid at closing was approximately $275 million, including a $250 million upfront payment and a $25 million milestone payment.
- Up to $727.5 million in additional milestone payments remains potentially payable, subject to milestone triggers and merger agreement terms.
- Lantheus acquired OCTEVY, a registrational-stage PET diagnostic imaging agent for neuroendocrine tumors, and Evergreen's CDMO business.
- The merger agreement was dated January 27, 2025, and the acquisition was first announced January 28, 2025.
The filing
Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 01, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.